Why the study?
Does metformin improve the lipid profile in women with polycystic ovary syndrome?
Does metformin improve the lipid profile in women with polycystic ovary syndrome?
Metformin therapy for 6 months significantly improves the lipid profile, particularly increasing HDL cholesterol, in women with polycystic ovary syndrome.
BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common metabolic and endocrine disorders affecting 5-10% of women in their reproductive age. The main objective of this study was to evaluate the effect of metformin on serum lipid profile in patients of polycystic ovary syndrome.METHODS: An observational prospective study conducted at Rajiv Gandhi Centre for Diabetes and Endocrinology and Department of Pathology, JN Medical College AMU from December 2012 to November 2015. All PCOS women were randomized into two group; one group were received Metformin therapy for 6 months duration and the other group were kept on placebo and followed for the same period. All studied women were subjected to measurement of overnight fasting lipid profile which included total cholesterol, triglycerides, high density lipoprotein cholesterol and low density lipoprotein cholesterol.RESULTS: For women who received Metformin, there was significant improvement in the biochemical profile with a significant p value of <0.001.CONCLUSION: Metformin have been shown to improve the lipid profiles leading to increase in the high density lipoprotein cholesterol, the main predictive of cardiovascular disease in the women with polycystic ovary syndrome. DOI: 10.21276/APALM.1226
No takes yet. Share an insight, caveat, or question.
Saeed et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: